Skip to content
Menu

Southern Company (The) 2026 Ser SONN

Full chart Compare
Set alert

Price alert · SONN

All alert types
51.02 USD +0.42 (+0.83%)

Regular-session close

51.02 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

51.00 Day range 51.83
51.02 52-week range 51.02
YTD
0.00%
1 year
0.00%

 

No chart data for this range yet.
Market cap
4.33M
Revenue (ttm)
55.88K
Shares out
3.01M
Forward P/E
-0.10
YTD return
0.00%
1-year return
0.00%
50-day average
3.46
200-day average
8.63
Volume
1.18M
Open
51.00
Previous close
50.60
Day's range
51.00 – 51.83
52-week range
51.02 – 51.02
Beta
1.04
Analysts
Strong Buy
Price target
160.00 (+213.6%)

Key statistics

Enterprise value
-2.23M
Price / sales
77.50
Price / book
0.36
Free cash flow
-9.88M
Total cash
3.55M
Total debt
150.19K
Return on equity
-264.57%
Short % of float
4.85%

Fundamental scorecard

5 of 25 checks passed on SONN’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2025.

Financials — quick view

All financials
SONN Revenue — quarterly 0
SONN Net income — quarterly -3.78M
SONN EPS — quarterly -0.95

Earnings

SONN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 12, 2025Dec 1, 20240.00———
Dec 19, 2024Sep 1, 20240.00———
Aug 14, 2024Jun 1, 20240.00-5.60——
May 14, 2024Mar 1, 20240.000.56——
Feb 14, 2024Dec 1, 20230.00-2.48——
Dec 18, 2023Sep 1, 20230.00———

Upgrades / downgrades

SONN analyst upgrades and downgrades
DateFirmActionFromTo
Dec 20, 2024Chardan CapitalmainBuyBuy
Aug 23, 2024Chardan CapitalmainBuyBuy
May 28, 2024Chardan CapitalmainBuyBuy
May 16, 2024EF HuttonmainBuyBuy
Feb 15, 2024Chardan CapitalmainBuyBuy
Nov 27, 2023Ladenburg Thalmanninit—Buy

About Southern Company (The) 2026 Ser

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on SONN — it syncs with the Stock Master app.

Insider holders

SONN insider holders
InsiderRelationLatest transactionDateShares held
BHATT NAILESHDirectorStock Award(Grant)Dec 10, 2023547
CINI JOHN KOfficerStock Award(Grant)Dec 10, 20232,116
CROSS JOHN HARRYChief Financial OfficerStock Award(Grant)Dec 10, 20231,588
DEXTER SUSANChief Technology OfficerStock Award(Grant)Dec 10, 20231,643
DYRNESS ALBERT DDirectorStock Award(Grant)Dec 10, 2023537
GRIFFITH DONALD J. CPADirectorStock Award(Grant)Dec 10, 2023375

Institution ownership

SONN institution ownership
Holder% heldSharesValueReported
Tower Research Capital LLC (TRC)0.01%378544Sep 29, 2024
Blackrock Inc.0.00%6593Sep 29, 2024

Fund ownership

SONN fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.10%3,0044.33KOct 30, 2024
Vanguard Extended Market Index Fund0.06%1,8412.65KSep 29, 2024
Fidelity Total Market Index Fund0.05%1,4182.04KOct 30, 2024
Fidelity Series Total Market Index Fund0.03%8501.22KOct 30, 2024